New antibody drug shows promise for severe asthma sufferers
NCT ID NCT05472324
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental drug called TQC2731 in 205 adults with severe asthma that is not well controlled by standard treatments. The drug is a lab-made antibody that blocks a protein involved in asthma inflammation. Participants received either one of three doses of TQC2731 or a placebo by injection every 4 weeks for about a year. The main goal was to see if the drug reduces the number of asthma attacks over a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQC2731 injection (a monoclonal antibody targeting TSLP)
What this could lead to
If successful, this could provide a new treatment option to reduce asthma attacks in people with severe asthma that is not well controlled by current medications.
What could go wrong
This is a Phase 2 trial with 205 participants, so results are still early. The drug may not prove effective or safe in larger studies, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GUANGZHOU FIRST PEOPLE's HOSPITAL
Guangzhou, Guangdong, 510180, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China